Viking Therapeutics heats up competition in obesity with impressive Phase 2 data
Arctic Aurora portfolio company Viking Therapeutics opened nearly 100% up on positive weight loss data from a Phase 2 study
Obesity is one of the largest societal and healthcare burdens globally. It is estimated to affect more than 650 million people, who are at a higher risk of developing more than 200 health complications including diabetes, cardiovascular problems, and fatty liver disease. In the recent years, multiple drugs have been developed to address this global challenge.
Arctic Aurora LifeScience and Arctic Aurora Biotech Select portfolio company Viking Therapeutics is a strong contender in the obesity space. Today, they announced competitive Phase 2 results of their drug candidate, VK2735. Obese patients in the trial achieved a placebo-adjusted weight loss of up to 13.1% after just 13 weeks. Importantly, weight loss did not plateau at 13 weeks and the treatment was effective in most patients with 88% of them achieving a ≥10% weight loss at the end of the trial. The side effects of the drug were comparable to other similar treatments.
VK2735 is a dual activator of the glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors. Effect on these receptors is associated with reduced body weight and appetite, and higher sensitivity to insulin. Among the drugs that are already approved, semaglutide (brand name Ozempic/Wegovy, marketed by Novo Nordisk) acts on GLP-1 while tirzepatide (Mounjaro/Zepbound by Eli Lilly) is a dual activator of the GLP-1/GIP receptors similarly to VK2735. According to consensus, the size of the obesity market will reach USD 100-150 billion and the peak sales of semaglutide and tirzepatide are expected to be USD 40 billion and USD 45 billion, respectively.
Latest news
Arctic Asset Management - Arctic Midt i Måneden - Halv pris, fantastisk avkastning og solide utbytter – børsoptimismen lever i Norden
Obligasjonsmarkedet har opplevd historisk stort volum og det norske aksjemarkedet har levert like god vekst som det amerikanske, men handles til halv pris (P/E). Samtidig byr Norden på sterke selskaper, solide dividender og gode muligheter for meravkastning gjennom håndplukkede porteføljer. I denne episoden av Arctic Midt i Måneden diskuterer vi hva som driver optimismen i markedet – fra rentebaner til resultatsesong. Bak mikrofonene sitter Albert Collett sammen med forvalterne Cathrine Foyn og Sindre Sørbye.
Arctic Asset Management - RNA therapy specialists Avidity Biosciences to be acquired by Novartis for USD 12 billion
On 26 October, Avidity Biosciences, a portfolio company of Arctic Aurora LifeScience, announced an agreement to be acquired by Novartis at a 46% premium to the previous close of the stock, or nearly 90% above the market value when rumours of the acquisition first emerged.
Arctic Asset Management - Markedskommentar september 2025
September ble en stabil børsmåned. Norden og Oslo var nær uendret med -0,1 % avkastning for både fondsindeksen OSEFX og den nordiske VINX Benchmark Cap målt i NOK. Så langt i år er Oslo Børs opp med 17,4 %. I USA steg S&P 500 indeksen med 3,6 % i september målt i dollar, og den europeiske STOXX 600 indeksen steg med 1,5 % målt i euro. Verdensindeksen (MSCI World NR) steg 2,4 % i september og er opp 2,9 % i norske kroner hittil i år.
Arctic Asset Management - Oncology company Merus to be acquired by Genmab for a 41% premium
Danish biotech Genmab to pay USD 8 billion to add Merus’ bispecific antibodies to their platform
Arctic Asset Management - Gene therapy from UniQure slows progression of Huntington’s disease by 75% in clinical trial
Breakthrough results from a three-year trial of a treatment for a severely debilitating neurological disease led to a surge of almost 250% in the stock price of Arctic Aurora LifeScience's portfolio company.
Arctic Asset Management - Arctic Midt i Måneden - Muligheter på børsen: Fantastisk inntjening, prising og et litt uvanlig rentebilde
Fantastisk inntjeningsvekst på Oslo Børs, fornuftig prising og et rentebilde som vi må følge godt med på - er tema i denne episoden av Arctic Midt i Måneden. Investeringsdirektør Albert Collett har med seg aksjeforvalter Sindre Sørbye og renteforvalter Vegard Kjølhamar i studio for å diskutere hva dette betyr for markedet fremover – og hvor mulighetene kan ligge for investorer.